May 24, 2018 5:46 PM ET

Pharmaceuticals

Company Overview of Fresenius Kabi USA, LLC

Company Overview

Fresenius Kabi USA, LLC develops, manufactures, and delivers pharmaceuticals and medical devices for critically and chronically ill patients. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. It offers pharmaceuticals used in the treatment of various therapeutic areas, such as anti-infective, anesthesia/analgesia, critical care, and oncology for hospitals, long-term care facilities, alternate care sites, and clinics in North America. The company also provides medical devices in the areas of transfusion technologies, infusion pumps, therapeutic apheresis, plasmapheresis system, and cell processing. It sells its products through...

3 Corporate Drive

Lake Zurich, IL 60047

United States

Founded in 1996

Phone:

847-550-2300

Key Executives for Fresenius Kabi USA, LLC

Chief Executive Officer and President
Chief Financial Officer and Executive Vice President
Chief Operating Officer and Executive Vice President
Age: 62
President of Pharmaceuticals of North America Region
Age: 58
President of Medical Devices - Region North America
Compensation as of Fiscal Year 2017.

Fresenius Kabi USA, LLC Key Developments

Fresenius Kabi USA Announces Voluntary Nationwide Recall of Midazolam Injection, USP, 2 mg/2 mL Due to Reports of Blister Packages Containing Syringes of Ondansetron Injection, USP, 4 mg/2 mL

Fresenius Kabi USA is voluntarily recalling Lot 6400048 of Midazolam Injection, USP, 2 mg/2 mL packaged in a 2 mL prefilled single-use glass syringe to the hospital/user level. The product mislabeled as Midazolam Injection, USP, 2 mg/2 mL contains syringes containing and labeled as Ondansetron Injection, USP, 4 mg/2 mL. A missed dose of midazolam may lead to ineffective sedation and/or anxiety related to patient recall of a surgical or diagnostic procedure. If a selection error occurs, a patient who may have received a pre-operative dose of ondansetron may inadvertently receive an additional dose of ondansetron. Midazolam is indicated for sedation, anxiety, and for induction of general anesthesia. It is packaged in a 2mL prefilled single-use glass syringe, packaged in a blister with 24 blisters per carton, NDC 76045-001-20, product code 766120. The affected Midazolam Injection, lot 6400048, expires July 2018. Ondansetron is indicated for the prevention of nausea and vomiting associated with cancer chemotherapy treatments and for prevention of postoperative nausea and/or vomiting. Product was distributed nationwide in the United States between May 12, 2017 and October 18, 2017 to wholesale distributors. Fresenius Kabi is notifying its distributors and customers by letter and is arranging for return of the recalled product. If health care facilities have the affected lot, they are to immediately discontinue distributing, dispensing or using the lot and return all units to Fresenius Kabi. Distributors are instructed to immediately notify their customers that have been shipped, or may have been shipped the product involved in this recall.

Fresenius Kabi Introduces Clofarabine Injection

Fresenius Kabi announced the immediate availability in the United States of Clofarabine Injection. Fresenius Kabi Clofarabine Injection is available as a single dose vial containing 20 mg per 20 mL Clofarabine. Clofarabine Injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine.

Fresenius Kabi and Terumo Cardiovascular Group Roll Out CATSmart Autotransfusion System in the United States

Fresenius Kabi and Terumo Cardiovascular Group reported the introduction of the CATSmart Autotransfusion System in the United States. CATSmart is Fresenius Kabi's next-generation continuous autotransfusion system and features continuous-flow technology for ease-of-use in operating rooms. CATSmart Autotransfusion System and related products will be distributed in the U.S. by Terumo Cardiovascular Group. Terumo Cardiovascular Group and Fresenius Kabi have signed an exclusive, five-year distribution agreement for CATSmart. Additional terms of the agreement were not disclosed. Autotransfusion systems are designed to reduce the need for allogeneic blood transfusions by re-infusing a patient's own lost blood during surgery.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fresenius Kabi USA, LLC, please visit www.fresenius-kabi.us. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.